Do GLP-1 users skip strength training? new survey aims to find out
NCT ID NCT07702461
First seen Jul 14, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study surveys adults taking GLP-1 medications (like semaglutide or tirzepatide) for diabetes or weight loss to understand their resistance training habits before and after starting the drug. The goal is to learn how often people strength train, what their workouts look like, and what barriers they face. Findings could help healthcare providers create better exercise guidance to protect muscle mass during weight loss.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- GLP-1 receptor agonist (e.g., semaglutide, liraglutide, tirzepatide)
- What this could lead to
- If this study reveals common gaps in resistance training among GLP-1 users, it could help doctors design better exercise recommendations to preserve muscle mass and physical function.
- What could go wrong
- This is an observational survey, not a treatment trial, so it cannot prove cause and effect. Results rely on self-reported habits, which may not be fully accurate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults residing in the United States who are current users of GLP-1 receptor agonist medications for type 2 diabetes, overweight or obesity, and/or weight management. Participants are recruited from community and online settings rather than from a single physical site. Sources include: IRB-approved flyers and posters displayed in relevant clinical settings (e.g., endocrinology, primary care) and community locations; social media outreach (posts and advertisements) directed at adults using GLP-1 receptor agonist medications; and clinic-based outreach in which participating clinic staff post handouts in waiting areas or distribute them to potentially interested patients during routine visits. Interested individuals self-refer by accessing an anonymous online Qualtrics survey link. The study team does not pre-screen, identify, or contact patients directly, and does not access medical records or protected health information at any point.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult aged 18 years or older * Currently taking a GLP-1 receptor agonist medication * On the GLP-1 receptor agonist for at least 3 months * Using the GLP-1 receptor agonist for type 2 diabetes, overweight or obesity, and/or weight management (self-reported) * Stable GLP-1 receptor agonist dose for the past 4 to 8 weeks * Able to read and respond to the survey in English * Willing and able to provide informed consent electronically Exclusion Criteria: * Currently or planning to become pregnant * Planned bariatric surgery within the next 3 months * Recent bariatric surgery (within the past 3 months) or other conditions that substantially alter resistance training capacity (e.g., advanced cancer cachexia, severe mobility-limiting conditions) * Unable to read or respond to the survey in English
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes (DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cost-Effectiveness and implementation of integrated Diabetes-Oral health care in oman: a health belief Model-Based intervention to enhance clinical, behavioral, and exploratory oral microbiome in health system outcomes in type 2 diabetes
- Real-World effectiveness, safety, and Patient-Reported outcomes of tirzepatide in adults with type 2 diabetes mellitus, obesity, or prediabetes in pakistan: a multicentre, prospective, observational cohort study
- Combined inspiratory muscle training and functional High-Intensity interval training promote respiratory, diaphragmatic, and aerobic adaptations in children with obesity
- Fibrinogen to albumin ratio (FAR) as a risk factor for type 2 diabetic Nephropathy(DN)
- Relationship between Collagen-Containing supplement use and muscle mass and body image following metabolic and bariatric surgery: a prospective observational study
- Can a dash of spice and protein shield muscle during Weight-Loss shots?